Engineering T cells is a broad description of techniques used to modify a T cells obtained from a patient or healthy donor. T cells are a subset of immune cells responsible for targeting and killing tumor cells. Once harvested from a patient or donor, the T cells can be engineered in a laboratory making them better capable of killing a specific tumor. Examples of adoptive cell therapies using engineered T cells are T cell receptor (TCR)-engineered T cells and chimeric antigen receptor (CAR) T cells.
-
Macrophages can mediate phagocytosis of cancer cells and cytotoxic tumor killing, and engage in effective bidirectional interactions with components of the innate and adaptive immune system....
OCT 05, 2023 | 1:00 AM
C.E. CREDITS
Organoids continue to gain traction in drug discovery efforts as they offer a more biologically relevant disease model than traditional approaches. But they aren't without challenges. Jo...
Webinars will be available for unlimited on-demand viewing after live event. Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the AS...
Join us for an educational webinar that delves into the fascinating world of Extracellular Vesicles (EVs) and their impact on biomedical research and medicine. In collaboration with ExoVecto...
In this third and final part of our translational cell and gene therapy webinar series we delve into cell therapy applications beyond immune oncology. Firstly, we will look into Miltenyi Bio...
Do you want to bring your CAR NK cell and Treg cell research into clinical applications? Watch this webinar and explore Miltenyi Biotec’s solutions to advance CAR NK cell and Treg-base...
Watch this webinar and explore Miltenyi Biotec’s solutions to advance CAR T-cell therapies – from basic research to process development and clinical manufacturing. Discover the p...
JUL 26, 2023 | 4:45 PM
C.E. CREDITS
Inefficient knock-in of transgene cargos limits the potential of cell-based medicines. In this study, we used a CRISPR nuclease that targets a site within an exon of an essential gene and de...
JUL 26, 2023 | 3:10 PM
C.E. CREDITS
Cell-based immunotherapy has become the new-generation cancer medicine, and “off-the-shelf” cell products that can be manufactured at large scale and distributed readily to treat...
JUL 26, 2023 | 11:20 AM
C.E. CREDITS
Chimeric antigen receptor (CAR)-reprogrammed immune cells offer exciting therapeutic potential for addressing oncology, autoimmune diseases, transplant medicine, and infections. However, cur...
The therapeutic use of chimeric antigen receptor T cells has achieved significant success in the treatment of B cells malignancies. Despite promising results in mouse tumor models, a similar...
Date: March 30, 2023 Time: 5:00pm (PST), 8:00pm (EST) March 31, 2023 9:00am (JST) Chimeric antigen receptor T cell (CAR-T) therapy is still challenging in targeting solid malignancies. The q...
FEB 22, 2023 | 9:00 AM
C.E. CREDITS
Date: February 22, 2023 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CET) Circular plasmid DNA has traditionally been used as a stable and efficient vector for gene expression and HDR-mediated...
FEB 22, 2023 | 5:30 AM
C.E. CREDITS
Many current technologies used in drug discovery and preclinical development programmes typically involve multi-step operations, extensive hands-on time, and lengthy liquid handling processe...
Date: February 15, 2023 Time: 7:00am (PST), 10:00pm (EST), 4:00pm (CET) While not all microscopy samples can fluoresce, all can scatter light, and this scattered light can be imaged. This ha...
DEC 07, 2022 | 9:00 AM
C.E. CREDITS
Date: December 07, 2022 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CET) Join us for an exciting live panel webinar, as we celebrate the 60th anniversary of Gibco Cell Culture. The panelists...
Date: November 16, 2022 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CET) Cell therapy offers a new treatment option for a wide variety of diseases. Most cell therapies involve injecting a spe...
Date: November 09, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CET) The field of cell and gene therapy is rapidly growing. In particular, the use of lentiviruses in CAR-T applications is...
The CRISPR revolution has begun and shows no signs of slowing down. CRISPR-Cas nuclease-based genome editing strategies hold great promise for the treatment of genetic disorders. However, a...